As more payers demand outcome studies, drug development costs will rise

12/3/2013 | Forbes

Drugmakers increasingly must conduct expensive outcome and comparative effectiveness studies to win not only FDA approval but also to be included on payers' formularies, writes John LaMattina, former president of Pfizer Global Research and Development. "The greater need for outcome studies will strain even the biggest pharmaceutical company R&D budgets," LaMattina writes. Yet outcome studies benefit patients, physicians and payers, and demonstrating the real value of new medicines will increase public confidence in their long-term health benefits, LaMattina writes.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR